Edesa Biotech, Inc. · NASDAQ:EDSA
Edesa Biotech — Investor Presentation (November 2025)
21 slides from Edesa Biotech's investor presentation, Nov 17, 2025
Slide 1: Corporate Presentation
f 3 \ | Edesa Biotech Corporate Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "
Slide 3: First-in-Class Development Pipeline
First-in-Class Development Pipeline Advancing First-in-Class Therapeutics for Immuno-Inflammatory Conditions Franchise Asset Program Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Status Comments CTA granted; Ph2 PoC and drug Anti-CXCL10 EB06 Vitiligo IND in manufacturing plans in (mAb) progress pr
Slide 4: EB06 - Vitiligo
EB06 - Vitiligo First-in-Class Anti-CXCL10 mAb
Slide 5: A Significant Unaddressed Market
A Significant Unaddressed Market Latent Market Comprised of Patients Waiting for Better Treatment Options Large Untapped Opportunity Large population but low proportion of patients seeking treatment due to lack of effective and safe treatments Diagnosed with 1.9M New therapies likely to drive market
Slide 6: Vitiligo: A Life-Altering Autoimmune Disease
Vitiligo IFNγ-CXCL10-CXCR3 Chemokine Axis Play a Key Role in the A Life-Altering Autoimmune Disease Pathogenesis of Vitiligo High Prevalence – 0.5 to 2% Global Population 50% Onset Before Age 20; Must be Managed for Decades Associated with Type 1 Diabetes and Lupus, among others Severe Quality of Li
Slide 7: EB06 – Targeting the Chemokine CXCL10
EB06 – Targeting the Chemokine CXCL10 Monoclonal Antibody that Directly Binds CXCL10 with High Affinity and Blocks it from Binding to CXCR3 IFNγ CXCL10 EB06 Drug Profile CXCR3A CXCR3B A fully human IgG1k monoclonal antibody Binds specifically to CXCL10 with high Ca2+ flux MAPK Akt PKA affinity Seque
Slide 8: CXCL10 Therapeutic Potential
CXCL10 Therapeutic Potential Therapeutically Targeting - Substantiated in Preclinical Studies IFNγ CXCL10 1 Melanocyte Apoptosis EB06 CXCL10/CXC3B mediates melanocyte apoptosis and activates anti-melanocytic CD8+ T-cells via CXCR3A 2 Knockout Mice CXCL10 -/- mice do not develop vitiligo CXCR3A CXCR3
Slide 9: Phase 2 Proof of Concept
Phase 2 Proof of Concept Moderate to Severe Non-Segmental (Generalized) Vitiligo Status CTA approved & IND in progress Subjects Total of 160 evaluable patients randomized 1:1:1 (EB06, 2.5 mg/kg: EB06, 5 mg/kg: EB06, 10mg/kg: Placebo) across up to 25 study centers Treatment Period EB06 or placebo wil
Slide 10: EB06: Anti-CXCL10 Monoclonal Antibody Summary and Next Steps
EB06: Anti-CXCL10 Monoclonal Antibody Summary and Next Steps Targeted Mechanism of Action 65 Subjects Dosed Biological Activity Phase 2 Ready Manufacturing Binds free and bound CXCL10 No Significant AEs Demonstrated CTA Approved Leading CDMO NEXT STEPS IND in progress CRO identified and ready to be
Slide 11: Daniluromer
Daniluromer First-in-Class sPLA2 Inhibitor Lead Indication: ACD Status: Topline Results Available
Slide 12: Allergic Contact Dermatitis (ACD)
Allergic Contact Dermatitis (ACD) The Leading Occupational Health Issue Related to Dermatology ACD Represents a Significant Unmet Need 3,000+ 70% 0 Contact Unable to fully No Known ACD is a Type IV Hypersensitivity Reaction Allergens avoid allergen Labelled Drugs Immune system sensitized following i
Slide 13: Significant Number of Patients with Chronic ACD
Significant Number of Patients with Chronic ACD $4.7B Total Addressable Market Opportunity 7 major markets (US, UK, Germany, France, Spain, Italy, Japan) and Canada1 “ Physicians strongly desire additional treatment options, especially for hands and face2 “ACD…can make you quit your job.” 30M Patien
Slide 14: Phase 2B Results – Composite CDSI and ISGA Scores
Phase 2B Results - – Composite CDSI and ISGA Scores 1.0% EB01 Met Primary Endpoint and a Key Secondary Endpoint with Statistical Significance Total CDSI Score* Total ISGA Score* Summary of Results Mean % Improvement from Baseline % Patients with a ≥2 Point Improvement from Baseline P Value = 0.027 P
Slide 15: Paridiprubart
Paridiprubart First-in-Class Anti-TLR4 mAb
Slide 16: Paridiprubart – Anti-Toll-like Receptor 4 (TLR4) Antibody
Paridiprubart – Anti-Toll-like Receptor 4 (TLR4) Antibody First-in-Class mAb that Specifically Blocks TLR4 Signalling 1 Paridiprubart interferes with TLR4 dimerization in a ligand independent manner Drug Profile NFκB AP-1 IRF3 A humanized IgG1k monoclonal antibody Binds to TLR4 with high affinity IL
Slide 17: Phase 3 - Baseline Characteristics - ARDS
Phase 3 - Baseline Characteristics - ARDS Phase 3 ITT Patient Population Encompassed Multiple Potential Etiologies Baseline Conditions Associated with ARDS* Pneumonia Types** 17% Bacterial 2% 29% Fungal 40% Viral Pneumonia 46% 6% Aspiration Unknown **Includes co-infections 20% ARDS Patients Sepsis 1
Slide 18: Baseline Characteristics - ICU
Baseline Characteristics - ICU Phase 3 Intent-to-Treat (ITT) Patient Population A total of 104 patients hospitalized in the ICU and under invasive mechanical ventilation Patients were required to have a positive Sars Cov2 test 5% (N=5) IMV Only 26% 36% (N=37) Acute Kidney Moderate Severity 38% ARDS
Slide 19: Phase 3 Results – Primary Endpoint 28-Day Mortality
Phase 3 Results – Primary Endpoint 28-Day Mortality Paridiprubart Met Primary and Secondary Endpoints with Statistical Significance Mortality at Day 28* Mortality at Day 60* Summary of Phase 3 Results n=104 n=104 P Value <0.001 P Value =0.003 28-Day Mortality Rate: Paridiprubart had a relative 52% 5
Slide 20: Paridiprubart Treatment Had Significant Impact on Clinical Improvement
Paridiprubart Treatment Had Significant Impact on Clinical Improvement Treatment Nearly Doubled the Chance of Recovery by Day 28 - ITT Estimated Proportion Achieving Secondary Endpoint a 2-pt Reduction in WHO Scale (p=0.032) Proportion of Patients Who Achieved at Least a 40% 2-Point Reduction in the
Slide 21: www.EdesaBiotech.com
www.EdesaBiotech.com investors@edesabiotech.com
Edesa Biotech — Investor Presentation (November 2025) on 6ix